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To investigate chronic lymphocytic leukemia (CLL)-initiating cells, we assessed NOTCH1 
mutation/expression in hematopoietic stem cells (HSCs). In NOTCH1-mutated CLL, we 
detected subclonal mutations in 57% CD34+/CD38− HSCs. NOTCH1 mutation was 
present in 66% CD34+/CD38+ progenitor cells displaying an increased mutational bur-
den compared to HSCs. Flow cytometric analysis revealed significantly higher NOTCH1 
activation in CD34+/CD38− and CD34+/CD38+ cells from CLL patients, regardless 
NOTCH1 mutation compared to healthy donors. Activated NOTCH1 resulted in overex-
pression of the NOTCH1 target c-MYC. We conclude that activated NOTCH1 is an early 
event in CLL that may contribute to aberrant HSCs in this disease.
Keywords: notch signaling, chronic lymphocytic leukemia, hematopoietic stem cells, nOTch1 mutation, 
cD34+ cells
inTrODUcTiOn
Chronic lymphocytic leukemia (CLL) is a mature B cell malignancy characterized by accumulation 
of clonal B cells in blood, bone marrow (BM), and lymphoid tissues. The search for CLL-initiating 
cells has never been successful. While several cell types have been suggested as giving rise to CLL, 
yet, there is no consensus as to its normal cellular counterpart (1). CLL cells have monoclonal immu-
noglobulin gene rearrangements, suggesting that lymphoid malignant stem cells originate after cells 
have committed to the lymphoid lineage. More recently, it has been reported that hematopoietic 
stem cells (HSCs) from CLL patients display the propensity to generate clonal B cells, suggesting the 
involvement of HSCs in lymphoid leukemogenesis (2).
In 2009, we first identified NOTCH1 mutations in CLL (3) and provided data on the adverse 
prognostic outcome associated with mutated NOTCH1 (4). More recently, independent studies 
confirmed the presence and the prognostic relevance of NOTCH1 mutations in CLL patients (5). All 
mutations resulted in NOTCH1 impaired degradation that led to NOTCH1 deregulated signaling, 
indicating that mutations could contribute to increase NOTCH activation in CLL (6, 7). Recently, 
analyses of peripheral blood CD34+CD19− cells and BM hematopoietic progenitors revealed 
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NOTCH1 mutation in some CLL samples (8, 9). Conversely, oth-
ers failed to demonstrate the presence of NOTCH1 mutations in 
circulating CD34+ cells from NOTCH1 mutated patients (10). In 
lymph node, CLL cells show NOTCH1 activation independent of 
mutation (11) and recent evidence have shown non-mutational 
NOTCH1 signaling with anti-apoptotic effects in peripheral 
blood CLL cells (12). However, the role of NOTCH1 signaling in 
the HSC compartment of CLL is still unknown.
MaTerials anD MeThODs
cell separation and Flow cytometry
We collected 28 BM samples including 21 CLL patients (15 
NOTCH1 mutated and 6 NOTCH1 wild type) and 7 healthy 
donors (HDs). BM and peripheral blood (PB) cells were collected 
under signed informed consent in accordance with Declaration 
of Helsinki and the Institutional Review Board of University of 
Perugia. Patient’s characteristics are described in Table S1 in 
Supplementary Material. BM cells from 10 NOTCH1 mutated 
CLL were single and/or double-sorted into CD34+CD38− HSCs 
and CD34+CD38+ progenitor fraction containing myeloid 
and lymphoid progenitors. Briefly, BM mononuclear cells were 
separated by Ficoll–Hypaque density gradient centrifugation. 
Flow cytometric analysis and cell-sorting were performed using 
the following antibodies: PE anti-CD34 and PC5 anti-CD38 
(Beckman Coulter), PerCP-Cy5.5 anti-CD34, FITC anti-CD19, 
PE-Cy7 anti-CD38, APC-H7 anti-CD10, V450 anti-CD3, and 
V500 anti-CD45 (BD Biosciences). NOTCH1 ICN on sorted 
populations was performed using PE anti-NOTCH1 (mN1A) 
(eBioscience). Cells were analyzed using a FACSCanto II and 
sorted using a FACS Aria III cell sorter (BD Biosciences).
Direct sanger sequencing
NOTCH1 gene mutational analysis was performed by directional 
sequencing of PCR fragments from genomic DNA. Primers and 
PCR conditions were as previously described (13).
allele-specific Pcr (as-Pcr), Droplet 
Digital Pcr (ddPcr), rT-Pcr
Allele-specific PCR was performed accordingly to a previ-
ously published protocol (13). ddPCR NOTCH1 probes assays 
(dHsaCP2500500 and dHsaCP2500501 Bio-Rad) were used to 
determinate the allelic burden of NOTCH1 in sorted cells. The 
droplet generated included DNA, Notch1 probes assays (1×), and 
ddPCR Supermix (2×) for Probes (no dUTP) (Bio-Rad). The mix 
was amplified by PCR and analyzed by QX200 Droplet Reader 
(Bio-Rad). Scatterplots depicting ddPCR results specifically for the 
NOTCH1 mutation assay. Real-time PCR analysis of c-MYC and 
Hes1 gene expression was performed in immunoselected CD34+ 
BM  cells. RNA was extracted using RNeasy Plus Kits (Qiagen, 
Hilden, Germany), and cDNA was obtained using Prime Script 
RT Master Mix (Takara Bio, Dalian, China). Real-time qPCR was 
performed with PCR Master Mix Power SYBER Green (Applied 
Biosystem, Warrington, UK) using the 7900HT fast Real-Time 
PCR System (Applied Biosystem). The primers sequence were F:5′-
CTTCTCTCCGTCCTCGGATTCT-3′ and R:5′- GAAGGTGATC 
CAGACTCTGACCTT-3′ for c-Myc, F:5′-AAGAAAGATAG 
CTCGCGGCAT-3′ and R:5′-CCAGCACACTTGGGTCTGT-3′ 
for Hes1 and F:5′- ATGGGGAAGGTGAAGGTCG-3′ and R:5′- 
GGGGTCATTGATGGCAACAATA-3′ for GAPDH. Relative 
fold change was normalized to GAPDH and calculated using the 
2−ΔΔCt method.
Western Blot analysis
Whole-cell lysates extracted from BM CD34+ cells (5 ×  105) 
of CLL patients and HDs were analyzed by western blot using 
an anti-NOTCH1 antibody (clone bTAN20) able to detect the 
300-kDa inactive precursor (FL), the 120-kDa transmembrane/
cytoplasmic/cytoplasmic (TM) subunit, and the active 100-kDa 
intracellular domain. Whole-cell lysates (3  µg) isolated from 
peripheral blood CD5+CD19+ CLL cells of NOTCH1 mutated 
patients were used as positive control.
statistical analysis
Statistical analyses were performed with GraphPad (GrapdhPad 
Software Inc., La Jolla, CA, USA). In the text, data are presented 
as mean ± SD and statistical differences between mean values 
were evaluated using the Student’s t-test and Mann–Whitney 
test.
resUlTs
hscs From cll Patients showed 
nOTch1 Mutation
The mean proportion of BM CD34+ cells before enrichment 
was 0.75 ± 0.44%. After the FACS sorting procedures, the mean 
purity of CD34+/CD38− cells was 94.58 ± 3.52% and CD34+/
CD38+ cells were 98.12 ± 1.34% (Figure 1A).
We initially analyzed the NOTCH1 mutational hotspot 
by Sanger sequencing. The CD34+/CD38− fraction did not 
contain NOTCH1-mutated cells. Then, a high sensitivity 
AS-PCR assay for the NOTCH1 mutation (13) indicated the 
presence of small HSCs mutated clones in 57% CLL samples. 
Densitometric analysis revealed a mean 6.4 ± 4.7% NOTCH1 
mutant allelic burden. Moreover, we used a ddPCR assay to 
validate NOTCH1 mutational data in HSCs by a more quantita-
tive method. We confirmed NOTCH1 mutations in two HSCs 
samples for which DNA was available that display an allelic 
ratio of 2.6 and 8.5%, respectively (Figure  1B). Altogether, 
these data confirm that NOTCH1 mutation is an early event 
in CLL hematopoiesis in a fraction of patients. Additionally, 
we measured the NOTCH1 mutational burden along specific 
stages of HSC differentiation in NOTCH1-mutated CLL 
patients. The mean percentage of the mutant allele progressively 
increased from 6.4 ± 4.7% in CD34+CD38− to 14.9 ± 11.3% 
in CD34+CD38+CD10+CD19+ cells, 22.7  ±  6.5% in 
CD34−CD38+CD10+CD19+ cells and 40.5 ±  4.3% in neo-
plastic CD5+CD19+ cells (Figure  1C). The analysis of the 
rearrangement status of the IgH gene revealed in both NOTCH1 
mutated and NOTCH1 unmutated CD34+CD38− HSCs the 
presence of a germline configuration in the half of the samples 
while the other 50% showed a clonal VDJ.
FigUre 1 | Analysis of NOTCH1 gene mutation and signaling in bone marrow (BM) hematopoietic stem cells (HSCs) and progenitors cells. (a) FACS-setting used 
for HSCs and progenitor cells sorting purification of one representative NOTCH1-mutated patient. Prospective cell separation included immunoselection (middle 
plot) and sorting (right plot) to ensure purity and lack of chronic lymphocytic leukemia (CLL) cell contamination for NOTCH1 mutation analysis. (B) Droplet digital 
PCR. Upper left panel is a schematic representation of positive and negative droplet distribution according to the fluorophore threshold indicated in magenta lines. 
Upper right and lower panels are representative scatterplots of wild type and NOTCH1 mutated HSCs and progenitor cells, respectively. (c) Results of the 
allele-specific PCR assay for delCT NOTCH1 mutation in HSCs (CD34+CD38−), pro-B progenitors (CD34+CD38+CD10+CD19+), pre-B cells 
(CD34−CD38+CD10+CD19+), and B neoplastic CLL (CD5+CD19+) from one NOTCH1-mutated CLL sample. CD5+CD19+ cells from a NOTCH1-WT patient 
were used as negative control and showed a normal band of 341 bp. Samples bearing the delCT NOTCH1 mutation showed an additional mutant band of 197 bp. 
(D) (i) Representative dot plots of healthy control, NOTCH1 wild type, and NOTCH1 mutated CLL BM samples showing expression of NOTCH1-ICN on CD34+/
CD38− HSCs and CD34+/CD38+ progenitors compartments. (ii) Bar graphs show the means ± SD of the percentage of NOTCH1-ICN positive cells. *p < 0.05, 
**p < 0.01, ***p < 0.001 according to Student’s t-test; (iii) real-time PCR analysis of c-MYC and Hes1 gene expression in CD34+ BM cells. mRNA levels were 
normalized to GAPDH and represented as fold change using healthy control cells as a reference.
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hscs From cll Patients have nOTch1 
aberrantly activated also in Unmutated 
nOTch1 Patients
Thus, we analyzed the NOTCH1 signaling status in HSCs and 
progenitor cells of NOTCH1-mutated and unmutated CLL 
samples. Physiologically, the active intracellular domain (ICN) of 
NOTCH1 accumulates in cells with activated NOTCH1 signaling 
as a result of a cleavage of the transmembrane (TM) subunit made 
by the y-secretase complex (14). Here, we used flow cytometry 
to quantitate the percentage of active NOTCH1-ICN in CD34+/
CD38− HSCs and CD34+CD38+ progenitors from the BM of 
CLL patients and HDs, used as control. As shown in Figure 1Di,ii, 
NOTCH1-ICN was significantly higher in CLL samples regard-
less the NOTCH1 mutational status compared to non-leukemic 
samples. Indeed, the mean percentage of CD34+/CD38−/
NOTCH1-ICN+ and CD34+/CD38+/NOTCH1-ICN+ popula-
tions in NOTCH1 WT and mutated CLL was significantly higher 
than HDs samples (73.4 ± 22.9 and 83 ± 16.4 vs 33.3 ± 14.8%; 
94.4 ± 7.3 and 92.8 ± 4.3 vs 47.9 ± 13.8%, respectively).
To demonstrate the capability of CD34+ CLL cells to activate 
NOTCH1 signaling pathway, we analyzed the levels of NOTCH1 
downstream transcriptional target gene. It has been demonstrated 
that NOTCH1 controls c-MYC expression in mature CLL cells 
overexpressing the NOTCH1-ICN (12). Thus, using quantitative 
reverse transcription-PCR, we found significantly higher mRNA 
expression levels of c-MYC in CD34+ cells from NOTCH1 
mutated and WT CLL samples compared to HD (3.5 ± 0.7 and 
2.6 ± 0.08 vs 1.3 ± 0.1) (Figure 1Diii). In addition, we showed 
higher Hes1 expression in CD34 + cells from CLL patients com-
pared to HD (4.2 ± 1.1 vs 1.1 ± 0.2) (Figure 1Diii), in line with 
upregulated NOTCH1 pathway.
Next, we analyzed whether the higher levels of NOTCH1 acti-
vation in HSCs and progenitors CLL samples were accompanied 
with increased NOTCH1 expression. We analyzed by western 
blot the expression levels of NOTCH1-TM subunit in CD34+ 
cells from BM aspirates of four NOTCH1-mutated CLL patients 
and three HDs (6). The median purity of immunoselected CD34+ 
cells was 97.3% (range 74–99.5%; Figure 2A). Results revealed 
that CD34+ samples from CLL patients always expressed the 
NOTCH1-TM protein. Conversely, in CD34+ cells from HDs, 
NOTCH1-TM was either absent or expressed at lower levels 
than those observed in CLL samples (Figure 2Bi,ii). These data 
demonstrated that high levels of NOTCH1 signaling activation 
correlated with NOTCH1-TM overexpression in the CD34+ 
hematopoietic compartment of CLL.
DiscUssiOn
The Notch pathway is genetically altered in a large number of 
hematopoietic and solid tumors (15). We recently reported that 
activating mutations of NOTCH1 are recurrently associated 
with CLL and predict poor outcome (3, 4). The identification of 
a somatic NOTCH1 mutation could help providing additional 
information on the cellular origin of CLL. Sanger sequencing 
analysis (13) failed to detect mutations in CD34+/CD38− HSCs 
fractions of CLL patients. However, the sensitivity of this method 
does not allow the identification of a mutation whose allelic 
representation is <10%. Thus, we used more sensitive PCR based 
methods in order to verify results obtained with direct sequencing.
The analysis of CD34+/CD38+ progenitors detected the 
NOTCH1 mutation in 57% of the samples. Damm et  al. (8) 
described a similar frequency of NOTCH1 mutation in multi-
potent progenitors of CLL samples performing NGS analysis on 
rare CD34+CD19− peripheral blood cells. Recently, the same 
analysis was conducted in immunoselected CD34+ BM cells that 
resulted NOTCH1-mutated in 8 out of 13 CLL samples (9). Here, 
we used two high sensitive PCR assays specific for NOTCH1 
mutation and employed FACS sorted CD34+CD38+ cells from 
BM aspirates. Additionally, we showed here that the NOTCH1 
mutational burden increased along specific stages of HSC dif-
ferentiation in NOTCH1-mutated CLL patients. This suggests 
that the NOTCH1 lesion is selected and expands during HSC 
differentiation toward a B neoplastic cell, thus strengthening the 
hypothesis that the genetic alteration is an initial event associated 
with the stepwise malignant transformation of CLL.
In normal human BM, CD34+CD38− populations do not 
rearrange the IgH gene (16), thus raising issues on the molecular 
purity of the sorted hematopoietic cell fractions presenting a VDJ 
rearrangement. Nevertheless, the high purity of HSC double-
sorted samples together with the sensitivity of the IgH method 
(5%) limited the risk of detecting small fractions of contaminating 
neoplastic B cells. The alternative option is that IgH rearrangement 
is the expression of a B neoplastic transactivation at the HSC level.
Recently, common nonmutational NOTCH1 activation has 
been described in mature CLL cells (12) raising the question of 
whether the same condition is present in HSCs to determine their 
aberrant behavior. The Notch1 signaling has been extensively 
analyzed in the contest of embryonic hematopoiesis. Ex vivo 
approaches suggest that Notch signaling can expand HSCs, rais-
ing the question of whether this is a physiologic Notch function. 
Gerhardt et  al. (17) correlated NOTCH1 with hematopoiesis 
in animal models and identified cell-autonomous functions for 
Notch1 signaling in fetal HSCs homeostasis. The present study 
indicated that the pool of CD34+ cells, including HSC and 
progenitor compartments, tend to have NOTCH1 aberrantly 
expressed and activated in CLL patients compared to HDs. 
NOTCH1 deregulation and overepression of c-Myc are independ-
ent of NOTCH1 mutational status. These data clearly show that 
expansion of the leukemic stem cell clone does not necessarily 
require a mutation to upregulate the NOTCH1 signaling, sug-
gesting the presence of extrinsic factors from the BM HSC niche 
that are capable of stimulating and promoting CLL-initiating cell 
clone expansion. In CLL patients, BM mesenchimal cells express 
different ligands, which might play a role in NOTCH1 activation 
(18). However, additional studies are warranted to compare the 
levels and type of these ligands in the BM of healthy people vs 
CLL patients. Alternatively, CLL-HSCs may have cell-intrinsic 
mechanisms activating NOTCH1, which involve alterations of 
NOTCH1 pathway regulators (19, 20) or aberrant regulation 
of NOTCH1 receptor recycling (21). This selective pressure 
might contribute to the onset of specific NOTCH1 mutations in 
a DNA context that is prone to spontaneous microdeletion (5) 
(Figure 2C).
FigUre 2 | Analysis of NOTCH1-TM expression in immunoselected CD34+ bone marrow (BM) cells. (a) Immunomagnetic cell sorting purification and phenotypic 
characterization of CD34+ cells from a representative chronic lymphocytic leukemia (CLL) BM used for NOTCH1 protein expression analysis. (B) (i and ii) Western 
blot analysis. Vertical lines indicate realignment of the same blot imaging. Protein loading was assessed by reprobing the blots with an anti-GAPDH antibody. The 
density of the bands corresponding to NOTCH1-TM was evaluated by densitometric analysis. Densitometry units (U) were calculated relative to GAPDH. Results 
revealed that CD34+ samples from CLL patients always expressed the NOTCH1-TM protein. (c) Schematic representation of clonal evolution during the 
development of CLL starting from hematopoietic stem cells (HSCs). NOTCH1 is found to be active at early stage of hematopoiesis (blue arrow) together with 
NOTCH1 mutations (lightning arrow) to which activated signaling might contribute. NOTCH1 activation persists and the mutated clone expands as the cell commit 
to mature CD19+CD5+CLL.
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Our discovery of NOTCH1 deregulated signal and mutations 
in CLL-HSC have significant therapeutic implications in this 
disease. A variety of approaches was used to inhibit NOTCH1 
for cancer therapy, including presenilin γ-secretasi inhibtors, 
trafficking modulators (22), and blocking antibodies. In the 
next future, it will be interesting to evaluate the effects of these 
anti-NOTCH1 drugs in the development of CD34+CD38− and 
CD34+CD38+ CLL populations.
In conclusion, our data confirmed the presence of NOTCH1 
mutations in HSCs of CLL patients and showed for the first 
time a common nonmutational NOTCH1 activation occurring 
early in CLL hematopoiesis and represent a rationale for the use 
of therapies targeting the NOTCH1 signaling in CLL aimed to 
inhibit the survival of CLL-initiating cells.
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